Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2012, Article ID 484591, 5 pages
http://dx.doi.org/10.1155/2012/484591
Clinical Study

Efficacy of a “Rescue” Ciprofloxacin-Based Regimen for Eradication of Helicobacter pylori Infection after Treatment Failures

1Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università di Sassari, Viale San Pietro, 8, 07100 Sassari, Italy
2Baylor College of Medicine, Michael E. DeBakey VAMC, 2002 Holcombe Boulevard, Houston, TX 77030, USA
3Sezione di Igiene, Dipartimento di Scienze Biomediche, Università di Sassari, Via Padre Manzella 4, 07100 Sassari, Italy

Received 13 February 2012; Accepted 10 March 2012

Academic Editor: Y. Yamaoka

Copyright © 2012 Maria Pina Dore et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Realdi, M. P. Dore, A. Piana et al., “Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies,” Helicobacter, vol. 4, no. 2, pp. 106–112, 1999. View at Google Scholar · View at Scopus
  3. D. Y. Graham, “Therapy of Helicobacter pylori: current status and issues,” Gastroenterology, vol. 118, no. 2, supplement 1, pp. S2–S8, 2000. View at Google Scholar · View at Scopus
  4. M. P. Dore, D. Y. Graham, R. Mele et al., “Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection,” The American Journal of Gastroenterology, vol. 97, no. 4, pp. 857–860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Dore, L. Marras, E. Maragkoudakis et al., “Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen,” Helicobacter, vol. 8, no. 4, pp. 307–309, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. R. J. Saad, P. Schoenfeld, M. K. Hyungjin, and W. D. Chey, “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis,” The American Journal of Gastroenterology, vol. 101, no. 3, pp. 488–496, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Gisbert, F. Bermejo, M. Castro-Fernández et al., “Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients,” The American Journal of Gastroenterology, vol. 103, no. 1, pp. 71–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Z. Jodlowski, S. Lam, and C. R. Ashby Jr., “Emerging therapies for the treatment of Helicobacter pylori infections,” Annals of Pharmacotherapy, vol. 42, no. 11, pp. 1621–1639, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Dresner, W. Coyle, R. Nemec, R. Peterson, T. Duntemann, and J. M. Lawson, “Efficacy of ciprofloxacin in the eradication of Helicobacter pylori,” Southern Medical Journal, vol. 89, no. 8, pp. 775–778, 1996. View at Google Scholar · View at Scopus
  10. S. Miehlke, W. Schneider-Brachert, C. Kirsch et al., “One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin,” Helicobacter, vol. 13, no. 1, pp. 69–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Labenz, E. Gyenes, U. Peitz, and G. Börsch, “Ciprofloxacin-omeprazole combination therapy for eradication of Helicobacter pylori,” Zeitschrift Fur Gastroenterologie, vol. 29, no. 4, pp. 143–145, 1991. View at Google Scholar
  12. R. P. Logan, P. A. Gummett, J. J. Misiewicz, Q. N. Karim, M. M. Walker, and J. H. Baron, “Two-week eradication regimen for metronidazole-resistant Helicobacter pylori,” Alimentary Pharmacology & Therapeutics, vol. 7, no. 2, pp. 149–153, 1993. View at Google Scholar · View at Scopus
  13. R. Vicente, B. Sicilia, S. Gallego, M. J. Revillo, J. Ducons, and F. Gomollon, “Helicobacter pylori eradication in patients with peptic ulcer after two treatments failure: a prospective culture-guided study,” Gastroenterologia y Hepatologia, vol. 25, no. 7, pp. 438–442, 2002. View at Google Scholar · View at Scopus
  14. M. Amini, H. Khedmat, and F. Yari, “Eradication rate of Helicobacter pylori in dyspeptic patients,” Medical Science Monitor, vol. 11, no. 4, pp. CR193–CR195, 2005. View at Google Scholar · View at Scopus
  15. K. Aminian, F. Farsad, A. Ghanbari, S. Fakhreih, and S. M. Hasheminasab, “A randomized trial comparing four Helicobacter pylori eradication regimens: standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy,” Trop Gastroenterol, vol. 31, pp. 303–307, 2010. View at Google Scholar
  16. J. E. Dominguez-Munoz, A. Leodolter, T. Sauerbruch, and P. Malfertheiner, “A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection,” Gut, vol. 40, no. 4, pp. 459–462, 1997. View at Google Scholar · View at Scopus
  17. F. Megraud, N. Lehn, T. Lind et al., “Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 11, pp. 2747–2752, 1999. View at Google Scholar
  18. National Committee for Clinical Laboratory Standards, “Performance standards for antimicrobial susceptibility testing. Tenth informational supplement,” Approved Standard M100-S10 (M7), National Committee for Clinical Laboratory Standards, Wayne, Pa, USA, 2000. View at Google Scholar
  19. Y. Yamaoka, T. Kodama, M. Kita, J. Imanishi, K. Kashima, and D. Y. Graham, “Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome,” Helicobacter, vol. 3, no. 4, pp. 241–253, 1998. View at Google Scholar · View at Scopus
  20. M. P. Dore, A. R. Sepulveda, H. El-Zimaity et al., “Isolation of Helicobacter pylori from sheep—implications for transmission to humans,” The American Journal of Gastroenterology, vol. 96, no. 5, pp. 1396–1401, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. P. Dore, A. R. Sepulveda, M. S. Osato, G. Realdi, and D. Y. Graham, “Helicobacter pylori in sheep milk,” The Lancet, vol. 354, no. 9173, p. 132, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Laine, R. Hunt, H. EI-Zimaity, B. Nguyen, M. Osato, and J. Spenard, “Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial,” The American Journal of Gastroenterology, vol. 98, no. 3, pp. 562–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Malfertheiner, F. Megraud, M. Giguere, and M. Riviere, “Quadruple therapy with bismuth subcitrate potassium, metronidazole, tetracycline, and omeprazole is superior to triple therapy with omeprazole, amoxicillin, and clarithromycin in the eradication of Helicobacter pylori,” Gastroenterology, vol. 138, supplement 1, pp. S–33, 2010. View at Publisher · View at Google Scholar
  24. L. A. Fischbach, S. V. van Zanten, and J. Dickason, “Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies,” Alimentary Pharmacology & Therapeutics, vol. 20, no. 10, pp. 1071–1082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Fischbach and E. L. Evans, “Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori,” Alimentary Pharmacology & Therapeutics, vol. 26, no. 3, pp. 343–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. P. Gisbert, M. Castro-Fernández, F. Bermejo et al., “Third-line rescue therapy with levofloxacin after two H. pylori treatment failures,” The American Journal of Gastroenterology, vol. 101, no. 2, pp. 243–247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. Gisbert, F. Bermejo, M. Castro-Fernández et al., “Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients,” The American Journal of Gastroenterology, vol. 103, no. 1, pp. 71–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Boyanova and I. Mitov, “Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents,” Expert Review of Anti-Infective Therapy, vol. 8, no. 1, pp. 59–70, 2010. View at Google Scholar · View at Scopus
  29. A. E. Simor, S. Ferro, and D. E. Low, “Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori,” Antimicrobial Agents and Chemotherapy, vol. 33, no. 1, pp. 108–109, 1989. View at Google Scholar · View at Scopus
  30. C. A. McNulty, J. C. Dent, G. A. Ford, and S. P. Wilkinson, “Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa,” Journal of Antimicrobial Chemotherapy, vol. 22, no. 5, pp. 729–738, 1988. View at Google Scholar · View at Scopus
  31. J. W. Stone, R. Wise, I. A. Donovan, and J. Gearty, “Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach,” Journal of Antimicrobial Chemotherapy, vol. 22, no. 1, pp. 92–93, 1988. View at Google Scholar · View at Scopus
  32. C. E. Forsmark, C. M. Wilcox, J. P. Cello et al., “Ciprofloxacin in the treatment of Helicobacter pylori in patients with gastritis and peptic ulcer,” Journal of Infectious Diseases, vol. 162, no. 4, pp. 998–999, 1990. View at Google Scholar · View at Scopus
  33. M. Romano, M. R. Iovene, M. I. Russo et al., “Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates,” Journal of Clinical Pathology, vol. 61, no. 10, pp. 1112–1115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Romano, A. Cuomo, A. G. Gravina et al., “Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial,” Gut, vol. 59, no. 11, pp. 1465–1470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Güzelbulut, M. Sezikli, Z. Akkan Çetinkaya et al., “Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice?” Minerva Medica, vol. 102, no. 3, pp. 171–176, 2011. View at Google Scholar · View at Scopus